Skip to main content
Explore URMC

Blood Cancer Research

BeckerWilmot Researchers Advance Treatments for Blood Cancers

“We're not settling for great care based on today's treatments. We want to lead the way to the next generation of therapies," says Jonathan Friedberg, M.D., M.M.Sc., director of Wilmot Cancer Institute. 
For more than 30 years, Wilmot Cancer Institute has had a nationally recognized program for blood cancer research. Our team of leukemia and lymphoma experts is leading efforts to develop new therapies to combat many types of blood cancers.
For example, Michael Becker, M.D., led a study that proves why leukemia is so difficult to treat. The study suggests the current approach to drug development should be adjusted to target a broader range of genes or signaling pathways.
Additionally, Omar Aljitawi, M.D., published findings that could make umbilical cord transplants a viable option for those with leukemia and lymphoma. He discovered a hormone called erythropoietin (EPO) may be important for effective cord blood transplants.  

Research Leads to Treatment Advances That Improve the Lives of People With Cancer

Make a Gift

Make your secure online gift today »